Tempus AI Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients

Reuters

2025/06/02

<a href="https://laohu8.com/S/TEM">Tempus AI</a> Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients

Tempus AI Inc. has announced the introduction of xM for treatment response monitoring $(TRM.AU)$, a liquid biopsy assay designed to detect molecular response to immune-checkpoint inhibitor $(ICI.AU)$ therapy in advanced solid tumors. This new assay is part of Tempus' expanding portfolio aimed at monitoring molecular response and minimal residual disease $(MRD.AU)$. Currently available for research use only, clinical availability is anticipated later this year. The xM for TRM assay tracks changes in circulating tumor DNA (ctDNA) dynamics over time, enabling early assessment of molecular response in patients undergoing ICI treatments. Tempus is set to present new data on xM for TRM at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, emphasizing the assay's potential to aid clinicians in monitoring treatment response and refining therapeutic strategies for patients with advanced cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602186479) on June 02, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2540174798"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540174798\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540174798?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-02 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540174798","market":"nz","top_or_hot":-1,"title":"Tempus AI Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tempus AI Inc. has announced the introduction of xM for treatment response monitoring <a href=\"https://laohu8.com/S/TRM.AU\">$(TRM.AU)$</a>, a liquid biopsy assay designed to detect molecular response to immune-checkpoint inhibitor <a href=\"https://laohu8.com/S/ICI.AU\">$(ICI.AU)$</a> therapy in advanced solid tumors. This new assay is part of Tempus' expanding portfolio aimed at monitoring molecular response and minimal residual disease <a href=\"https://laohu8.com/S/MRD.AU\">$(MRD.AU)$</a>. Currently available for research use only, clinical availability is anticipated later this year. The xM for TRM assay tracks changes in circulating tumor DNA (ctDNA) dynamics over time, enabling early assessment of molecular response in patients undergoing ICI treatments. Tempus is set to present new data on xM for TRM at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, emphasizing the assay's potential to aid clinicians in monitoring treatment response and refining therapeutic strategies for patients with advanced cancers.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602186479) on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempus AI Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-02 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tempus AI Inc. has announced the introduction of xM for treatment response monitoring <a href=\"https://laohu8.com/S/TRM.AU\">$(TRM.AU)$</a>, a liquid biopsy assay designed to detect molecular response to immune-checkpoint inhibitor <a href=\"https://laohu8.com/S/ICI.AU\">$(ICI.AU)$</a> therapy in advanced solid tumors. This new assay is part of Tempus' expanding portfolio aimed at monitoring molecular response and minimal residual disease <a href=\"https://laohu8.com/S/MRD.AU\">$(MRD.AU)$</a>. Currently available for research use only, clinical availability is anticipated later this year. The xM for TRM assay tracks changes in circulating tumor DNA (ctDNA) dynamics over time, enabling early assessment of molecular response in patients undergoing ICI treatments. Tempus is set to present new data on xM for TRM at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, emphasizing the assay's potential to aid clinicians in monitoring treatment response and refining therapeutic strategies for patients with advanced cancers.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602186479) on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4611","symbol_name":"AI医疗","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDLbQy3MV:1","article_id":"2540174798","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540174798","pubTimestamp":1748867414,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tempus AI Inc. has announced the introduction of xM for treatment response monitoring , a liquid biopsy assay designed to detect molecular response to immune-checkpoint inhibitor  therapy in advanced solid tumors. This new assay is part of Tempus' expanding portfolio aimed at monitoring molecular response and minimal residual disease . Currently available for research use only, clinical availability is anticipated later this year. The xM for TRM assay tracks changes in circulating tumor DNA  dynamics over time, enabling early assessment of molecular response in patients undergoing ICI treatments. Tempus is set to present new data on xM for TRM at the 2025 American Society of Clinical Oncology  Annual Meeting, emphasizing the assay's potential to aid clinicians in monitoring treatment response and refining therapeutic strategies for patients with advanced cancers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4611":"AI医疗","BK4121":"生命科学工具和服务","TEM":"Tempus AI","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4613":"AI应用软件"},"translate_title":"Tempus AI Inc.推出xM Assay以增强对晚期癌症患者免疫治疗反应的监测","themeId":"715ea2be3c240e157af090fc4d598bc8","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":0.9},"content_text":"Tempus AI Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients\n    \n\n        Tempus AI Inc. has announced the introduction of xM for treatment response monitoring $(TRM.AU)$, a liquid biopsy assay designed to detect molecular response to immune-checkpoint inhibitor $(ICI.AU)$ therapy in advanced solid tumors. This new assay is part of Tempus' expanding portfolio aimed at monitoring molecular response and minimal residual disease $(MRD.AU)$. Currently available for research use only, clinical availability is anticipated later this year. The xM for TRM assay tracks changes in circulating tumor DNA (ctDNA) dynamics over time, enabling early assessment of molecular response in patients undergoing ICI treatments. Tempus is set to present new data on xM for TRM at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, emphasizing the assay's potential to aid clinicians in monitoring treatment response and refining therapeutic strategies for patients with advanced cancers.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602186479) on June 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}